Reuters -- Celgene Corp said on Friday that initial results from a trial of its cancer drug Revlimid showed it delayed disease progression in patients with multiple myeloma who had undergone a stem cell transplant.
Reuters -- Celgene Corp said on Friday that initial results from a trial of its cancer drug Revlimid showed it delayed disease progression in patients with multiple myeloma who had undergone a stem cell transplant.
